Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase II for Thymic Carcinoma. According to GlobalData, Phase II drugs for Thymic Carcinoma does not have sufficient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback